Dynamic conditional correlation models in a multiple financial asset portfolio
M Groth, P Thåström - The Journal of Alternative Investments, 2009 - search.proquest.com
A key concept in risk and portfolio management is diversification, which has recently come
under intense scrutiny following dramatic market movements where historical correlation …
under intense scrutiny following dramatic market movements where historical correlation …
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
… The primary endpoint was independently confirmed objective response rate per Response
Evaluation Criteria in Solid Tumors version 1.1 (central review), assessed in prespecified …
Evaluation Criteria in Solid Tumors version 1.1 (central review), assessed in prespecified …
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
…, D Tayama, S Mariathasan, A Mecke, AC Thåström… - The Lancet, 2020 - thelancet.com
… Treatment was administered until investigator-assessed disease progression per RECIST 1.1
or … All authors verify that this study was done per protocol and vouch for data accuracy and …
or … All authors verify that this study was done per protocol and vouch for data accuracy and …
IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy …
…, JA Arranz Arija, E Kikuchi, A Mecke, AC Thastrom… - 2018 - ascopubs.org
… Key secondary efficacy endpoints include investigator-assessed ORR, DOR and PFS per
RECIST v1.1 (for atezo vs placebo + chemo arms). Safety, biomarkers and other exploratory …
RECIST v1.1 (for atezo vs placebo + chemo arms). Safety, biomarkers and other exploratory …
Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): updated OS, safety and biomarkers from the Ph II IMvigor210 …
…, JL Perez-Gracia, EG Pulido, A Thåström… - Annals of …, 2016 - annalsofoncology.org
… Thåström … ORR (central review) and immune-modified RECIST ORR (per investigator).
PD-L1 status on immune cells (IC) was scored centrally (SP142 IHC assay): IC2/3, 1, 0. …
PD-L1 status on immune cells (IC) was scored centrally (SP142 IHC assay): IC2/3, 1, 0. …
[HTML][HTML] IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs …
…, JR Li, A Mecke, S Mariathasan, A Thastrom… - Annals of …, 2019 - Elsevier
… Tumours were assessed at baseline and every 9 wk until (INV)-assessed PD per RECIST
1.1 or other events. Coprimary efficacy endpoints are INV-assessed PFS and OS (Arm A vs C) …
1.1 or other events. Coprimary efficacy endpoints are INV-assessed PFS and OS (Arm A vs C) …
A genomic code for nucleosome positioning
E Segal, Y Fondufe-Mittendorf, L Chen, AC Thåström… - Nature, 2006 - nature.com
… Error bars are sem d, Number of all pairs of proximal stable nucleosomes per centre-to-centre
nucleosome distance, compared to the mean (black) and standard deviation (grey) in 100 …
nucleosome distance, compared to the mean (black) and standard deviation (grey) in 100 …
Measurement of histone–DNA interaction free energy in nucleosomes
A Thåström, PT Lowary, J Widom - Methods, 2004 - Elsevier
… In other words, the use of the dialysis method per se does not eliminate all kinetic obstacles
to reversible equilibrium formation of nucleosomes. These facts limit the range of affinity of …
to reversible equilibrium formation of nucleosomes. These facts limit the range of affinity of …
Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
…, N Cui, S Mariathasan, AC Thastrom… - 2016 - ascopubs.org
… The primary efficacy endpoint was confirmed ORR assessed per RECIST v1.1 (central
independent review facility) using a data cutoff of Sep 14, 2015. Results: 119 efficacy/safety-…
independent review facility) using a data cutoff of Sep 14, 2015. Results: 119 efficacy/safety-…
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
…, JL Grogan, R Banchereau, N Leng, AC Thastrom… - Nature medicine, 2020 - nature.com
… The total cell density was used to impute the volume of single-cell suspension needed in
the reverse transcription master mix, aiming to achieve ~6,000 cells per sample. Libraries and …
the reverse transcription master mix, aiming to achieve ~6,000 cells per sample. Libraries and …